Ofatumumab and the Anti-CD20 Class

Video

An expert discusses takeaways about the anti-CD20 monoclonal antibody class of disease-modifying therapies for patients with relapsing multiple sclerosis through the lens of ofatumumab (Kesimpta; Novartis).

Transcript below.

Patricia K. Coyle, MD: Clinicians should think about [these real-world ofatumumab data from the standpoint of this] as a class of medications. The anti-CD20s are high-efficacy treatment [for multiple sclerosis], and are relatively well-tolerated. Ofatumumab [Kesimpta; Novartis] is joining this group. As people recall, you give this subcutaneously at home every 4 weeks, and you typically don't need to pre-medicate for the injection. So it's well-tolerated. And because of that, it's fitting right in. The use [of this agent] is there immediately because I think people feel comfortable with the anti-CD20 class.

We'll continue to look at this cohort, and as the numbers get larger and larger, it's going to give us a more and more accurate picture of how individuals in the United States are using this new disease-modifying therapy. I think potentially, that will give us some very important insights.

Related Videos
Opeolu Adeoye, MD, MS; Andrew Barerrto, MD, MS
David Z. Rose, MD
Shadi Yaghi, MD, associate professor of neurology at Brown University
Matthew B. Harms, MD, MDA Medical Advisor and Care Center Director, Associate Professor of Neurology at Columbia University Irving Medical Center - Eleanor and Lou Gehrig ALS Center.
Ava L. Liberman, MD, medical director of the Stroke Center at Weill Cornell Medicine
© 2024 MJH Life Sciences

All rights reserved.